Live Feed

SUZHOU, China, April 29, 2026 (GLOBE NEWSWIRE) -- YXT.com Group Holding Limited (NASDAQ:YXT) ("YXT.com" or the "Company"), a provider of AI-enabled enterprise productivity solutions, today announced that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2025 with the Securities and Exchange Commission on April 29, 2026 Eastern Time. The annual report can be accessed on the Company's investor relations website at https://ir.yxt.com. About YXT.com YXT.com (NASDAQ:YXT) is a technology company focusing on enterprise productivity solutions. With a mission to "Empower people and organization development through technology," the Company strives to become the sup

Veradermics, Incorporated ("Veradermics") (NYSE:MANE), a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced the pricing of its upsized public offering of 3,843,790 shares of its common stock at a public offering price of $100.00 per share. All of the shares are being offered by Veradermics. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be approximately $384.4 million. The offering is expected to close on May 1, 2026, subject to the satisfaction of customary closing conditions. In addition, Veraderm

L3Harris Technologies (NYSE:LHX) today announced it has confidentially submitted a draft registration statement on Form S-1 with the U.S. Securities and Exchange Commission (the "SEC") related to the proposed initial public offering of common stock in its Missile Solutions business. The number of shares to be offered and the price range for the proposed offering have not yet been determined. The initial public offering is subject to market and other conditions and the completion of the SEC's review process. This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities. Any offers, solicitations or offers to buy, or any sales of securities wi

SCHEDULE 13D/A - Atlas Lithium Corp (0001540684) (Subject)

4 - IPERIONX Ltd (0001898601) (Issuer)

SCHEDULE 13G/A - INTEST CORP (0001036262) (Subject)

S-1MEF - Veradermics, Inc (0001827635) (Filer)

4 - Estrella Immunopharma, Inc. (0001844417) (Issuer)

SAN JOSE, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- California Water Service Group ((Group or Company, NYSE:CWT), a leading publicly traded water utility serving California, Hawaii, New Mexico, Washington, and Texas, today reported first quarter 2026 results and provided an update on the revised proposed decision issued by the California Public Utilities Commission (CPUC) on April 29, 2026 (revised PD) on California Water Service Company's (Cal Water's) 2024 California General Rate Case (2024 CA GRC). First Quarter 2026 in Line with Expectations Given Pending Decision on 2024 CA GRC The Company reported that first-quarter 2026 results were in line with expectations as the Company awaits

SCHEDULE 13D - LIBERTY DEFENSE HOLDINGS, LTD. (0001919776) (Subject)

SCHEDULE 13G/A - TECK RESOURCES LTD (0000886986) (Subject)

Exclusive Investor Lunch Attended by Approx. 30 Key Stakeholders Highlights Strategic Progress and Market Momentum Leadership Outlines Dual-Engine Growth Strategy and Device–Data–Brain Flywheel Across EV and Robotics Segments Investors Gain Firsthand Experience of Latest Products, including FF 91 and FX Super One, FF Master and FX Aegis Faraday Future Intelligent Electric Inc. (NASDAQ:FFAI) ("Faraday Future", "FF" or "Company"), a California-based global shared intelligent electric mobility ecosystem company, today announced the successful hosting of an exclusive investor and institutional lunch held in New York City on April 29, 2026. The event, led by Global President, Jerry Wan

4 - Navios Maritime Partners L.P. (0001415921) (Issuer)

SCHEDULE 13G/A - Coherus Oncology, Inc. (0001512762) (Subject)

– In a deal secured by Sphere Abacus, a Bell Media company, AMC Global Media secures U.S. streaming rights for the contemporary mystery thriller –– YAGA is produced by Blink49 Studios and Front Street Pictures, and stars Carrie-Anne Moss, Noah Reid, Clark Backo, Hudson Williams, and more –TORONTO, April 29, 2026 /CNW/ - Crave confirmed today its original series YAGA, produced by Blink49 Studios, is set to debut in the U.S. later this year exclusively on AMC+. The deal was secured by Sphere Abacus, a Bell Media company, and comes on the heels of the recent announcement that the series was acquired by Sky for the United Kingdon and Ireland. Additional territories to be announced soon. "The ong

CALGARY, Alberta, April 29, 2026 (GLOBE NEWSWIRE) -- This news release contains "forward-looking information and statements" within the meaning of applicable securities laws. For a full disclosure of the forward-looking information and statements and the risks to which they are subject, see the "Cautionary Statement Regarding Forward-Looking Information and Statements" later in this news release. This news release contains references to certain Financial Measures and Ratios, including Adjusted EBITDA (earnings before income taxes, (gain) loss on investments and other assets, finance charges, foreign exchange, gain on asset disposals and depreciation and amortization), Net Capital Spending,

Achieved Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back Pain Activity Report for Quarter Ended March 31, 2026 (Appendix 4C) NEW YORK, April 29, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, today provided highlights of its recent activities for the third fiscal quarter ended March 31, 2026. "We've had a busy and exciting March quarter marked by a series of major achievements. Ryoncil® revenues are now approaching US$100 million since last year's launch, we have substantially improved our net operating cash spend, our pivotal trial in inflammatory back pain has succes

First Northern Community Bancorp ((the "Company", NASDAQ:FNRN), holding company for First Northern Bank ("First Northern" or the "Bank"), today reported net income of $5.9 million, or $0.36 per diluted share, for the three months ended March 31, 2026, up 60.9% compared to net income of $3.7 million, or $0.22 per diluted share, for the three months ended March 31, 2025. Total assets as of March 31, 2026, were $1.92 billion, an increase of $48.8 million, or 2.6%, compared to March 31, 2025. Total net loans as of March 31, 2026, were $1.06 billion, an increase of $23.8 million, or 2.3%, compared to March 31, 2025. The increase in net loans was primarily driven by growth in commercial loans,

Compañia de Minas Buenaventura S.A.A. ("Buenaventura" or "the Company") (NYSE:BVN, Lima Stock Exchange: BUE.LM)), Peru's largest publicly-traded precious metals mining company, today announced results for the first quarter (1Q26) ended March 31, 2026. All figures have been prepared in accordance with IFRS (International Financial Reporting Standards) on a non-GAAP basis and are stated in U.S. dollars (US$). First Quarter 2026 Highlights: Gold production increased by 8% year-over-year (YoY) primarily driven by the ramp-up of operations at San Gabriel. Consolidated silver production increased by 6% YoY, reflecting higher output at El Brocal, Uchucchacua and Tambomayo. Lead and zinc produ

ROCHESTER, N.Y., April 29, 2026 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (OTC:VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in Alzheimer's, Huntington's disease, and cancer today released financial results for the year ended December 31, 2025. The financial statements have been posted on the company website. About Vaccinex, Inc. Vaccinex, Inc. is a clinical-stage immunotherapy company engaged in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including neurodegenerative diseases, cancer, and autoimmune disorders, and is currently initiating a new Phase 2b study in A